Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide. Its prevention depends on identifying, before the first clinical event, who will benefit from treatment. Over the past six decades, that task has been carried out by a sequence of multivariable risk equations — from the Framingham-derived scores to the US Pooled Cohort Equations, the United Kingdom’s QRISK3, Europe’s SCORE2, and most recently the American Heart Association’s PREVENT equations. Each generation has expanded the input variables, widened the age range, and improved calibration. Yet external validation continues to show systematic miscalibration and weak transportability across populations. This review synthesises how contemporary epidemiology is responding to those limitations on two fronts. First, predictive data sources are broadening: electronic health record-derived machine learning models, wearable and sensor-derived physiological signals, and polygenic risk scores are extending discrimination and covering patients older fixed equations exclude. Second, and less often integrated, digital health interventions — from automated text-message programmes to smartphone-linked blood-pressure management — have demonstrated modest but reproducible reductions in the very risk factors that risk equations estimate: LDL cholesterol, systolic blood pressure, and medication adherence. We argue that the central methodological gap is no longer prediction accuracy in isolation. It is the design of closed-loop systems in which a risk estimate triggers, adapts to, and measures the response of a digital intervention. We examine where the evidence is robust, where disagreements persist over the clinical utility of polygenic scores and the generalisability of wearable-derived data, and what an implementation-focused research agenda should now prioritise.
References
[1] Chow, C. K., Redfern, J., Hillis, G. S., Thakkar, J., Santo, K., Hackett, M. L., Jan, S., Bompoint, S., Billot, L., Grobbee, R., Barqawi, G., Arrieta, A., & Webster, R. (2015). Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: A randomized clinical trial. JAMA, 314(12), 1255–1265. https://doi.org/10.1001/jama.2015.10945
[2] Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Sr., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., Robinson, J. G., Schwartz, J. S., Shero, S. T., Smith, S. C., Jr., Sorlie, P., Stone, N. J., & Wilson, P. W. F. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation, 129(25 Suppl 2), S49–S73. https://doi.org/10.1161/01.cir.0000437741.48063.64
[3] Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ, 357, j2099. https://doi.org/10.1136/bmj.j2099
[4] Khan, S. S., Coresh, J., Pencina, M. J., et al. (2023). Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation, 148(24), 1982–2004. https://doi.org/10.1161/CIR.0000000000001191
[5] McManus, R. J., Mant, J., Franssen, M., Nickless, A., Schwartz, C., Hodgkinson, J., Davies, M., Ryan, V., English, P., Wang, J., Francis, D., Roderick, P. J., & Sutcliffe, P. (2018). Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. The Lancet, 391(10124), 949–959. https://doi.org/10.1016/S0140-6736(18)30306-1
[6] McManus, R. J., Little, P., Stuart, B., Morton, K., Raftery, J., Kelly, J., Bradbury, K., Zhang, J., Zhu, S., Murray, E., Jones, N., Ige, J., & Mair, J. (2021). Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: Randomised controlled trial. BMJ, 372, m4858. https://doi.org/10.1136/bmj.m4858
[7] O’Sullivan, J. W., Raghavan, S., Marquez-Luna, C., Luzum, J. A., Damrauer, S. M., Ashley, E. A., O’Donnell, C. J., Willer, C. J., & Natarajan, P. (2022). Polygenic risk scores for cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 146(5), e93–e118. https://doi.org/10.1161/CIR.0000000000001077
[8] Patel, A. P., et al. (2023). A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. Nature Medicine, 29(7), 1793–1803. https://doi.org/10.1038/s41591-023-02429-x
[9] Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., Hung, G., Lee, J., Waalen, J., Silva, C. T., Odisho, F., Maguire, M., & Talati, N. (2019). Large-scale assessment of a smartwatch to identify atrial fibrillation. New England Journal of Medicine, 381(20), 1909–1917. https://doi.org/10.1056/NEJMoa1901183
[10] Ridker, P. M., & Cook, N. R. (2016). The Pooled Cohort Equations 3 years on: Building a stronger foundation. Circulation, 134(23), 1789–1791. https://doi.org/10.1161/CIRCULATIONAHA.116.025693
[11] Siopis, G., Moschonis, G., Eweka, E., Jung, J., Kwasnicka, D., Yeboah-Asiamah Asare, B., Kodithuwakku, V., Willems, R., Verhaeghe, N., Annemans, L., Vedanthan, R., Oldenburg, B., & Manios, Y. (2023). Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with hypertension: A systematic review and meta-analysis of randomised controlled trials. The Lancet Digital Health, 5(3), e144–e159. https://doi.org/10.1016/S2589-7500(23)00002-X
[12] Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., Cosyns, B., Czernin, J., Desormais, I., Di Angelantonio, E., Freiberger, E., Franco, O. H., Gonzalo Ordóñez, A., Giampaoli, S., Graeff, E., … Wegler, A. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 42(34), 3227–3337. https://doi.org/10.1093/eurheartj/ehab484
[13] Ward, A., Sarraju, A., Chung, S., Li, J., Harrington, R., Heidenreich, P., Palaniappan, L., Scheinker, D., & Rodriguez, F. (2022). Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population. npj Digital Medicine, 5, 150. https://doi.org/10.1038/s41746-022-00695-7

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Journal of Public Health and Preventive Medicine